Loading...
•
Mar 31, 2023
Lineage Q1 2023 Earnings Report
Lineage Cell Therapeutics reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
Lineage Cell Therapeutics reported a decrease in revenue driven by less collaboration and licensing revenue recognized from the Roche Agreement, while operating expenses also decreased due to lower litigation and legal expenses.
Lineage team advanced clinical and preclinical cell transplant programs.
Continued support of existing alliances and establishing new ones.
Supported Phase 2a clinical study of OpRegen in patients with GA secondary to AMD in partnership with Roche and Genentech.
Established new collaborations with CIRM and the Christopher & Dana Reeve Foundation to support a new SCI conference.
Forward Guidance
Lineage expects its cash, cash equivalents, and marketable securities to support planned operations into Q3 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...